open access publication

Article, 2024

Structural and mechanistic insights into Quinolone Synthase to address its functional promiscuity

Communications Biology, ISSN 2399-3642, Volume 7, 1, 10.1038/s42003-024-06152-2

Contributors

Vijayanathan M. 0000-0001-9806-3736 [1] [2] Vadakkepat A.K. [3] [4] Mahendran K.R. 0000-0003-2549-9250 [1] Sharaf A. 0000-0002-3436-9290 [5] Frandsen K.E.H. 0000-0002-7136-9820 [2] Bandyopadhyay D. [6] Pillai M.R. [1] Soniya E.V. 0000-0003-4248-3891 (Corresponding author) [1]

Affiliations

  1. [1] Rajiv Gandhi Centre for Biotechnology
  2. [NORA names: India; Asia, South];
  3. [2] University of Copenhagen
  4. [NORA names: KU University of Copenhagen; University; Denmark; Europe, EU; Nordic; OECD];
  5. [3] Indian Institute of Science
  6. [NORA names: India; Asia, South];
  7. [4] University of Leicester
  8. [NORA names: United Kingdom; Europe, Non-EU; OECD];
  9. [5] University of Konstanz
  10. [NORA names: Germany; Europe, EU; OECD];

Abstract

Quinolone synthase from Aegle marmelos (AmQNS) is a type III polyketide synthase that yields therapeutically effective quinolone and acridone compounds. Addressing the structural and molecular underpinnings of AmQNS and its substrate interaction in terms of its high selectivity and specificity can aid in the development of numerous novel compounds. This paper presents a high-resolution AmQNS crystal structure and explains its mechanistic role in synthetic selectivity. Additionally, we provide a model framework to comprehend structural constraints on ketide insertion and postulate that AmQNS’s steric and electrostatic selectivity plays a role in its ability to bind to various core substrates, resulting in its synthetic diversity. AmQNS prefers quinolone synthesis and can accommodate large substrates because of its wide active site entrance. However, our research suggests that acridone is exclusively synthesized in the presence of high malonyl-CoA concentrations. Potential implications of functionally relevant residue mutations were also investigated, which will assist in harnessing the benefits of mutations for targeted polyketide production. The pharmaceutical industry stands to gain from these findings as they expand the pool of potential drug candidates, and these methodologies can also be applied to additional promising enzymes.

Funders

  • Villum Foundation Experiment
  • MBU
  • Council of Scientific and Industrial Research
  • Indian Institute of Science
  • Department of Biotechnology, Ministry of Science and Technology

Data Provider: Elsevier